Investors ini­tially pushed the stock up by focusing on the bright side of the ruling. The Supreme Court said Myriad does have the legal right to patent forms of human’s genetic code that can be pre­dic­tive of who might con­tract breast or ovarian cancer, says Michael Ben­nett, pro­fessor of law at North­eastern Uni­ver­sity. Investors may have been expecting the com­pany to lose all its claims, so the fact were were upheld was a com­fort, he says.


Read the article at USA Today →